― By Carmen F. Alfonso, D.O.
PLTP as a Therapeutic for Atherosclerosis — Development Dashboard
The Critical Scientific Tension
The dashboard surfaces the core paradox that makes PLTP uniquely complex: the 2021 Jiang lab inducible knockout paper is arguably the most compelling preclinical plaque regression data in the atherosclerosis field, yet the 2024 UK Biobank Mendelian randomization (N=318,734) shows OR 0.99 for CAD — a null result that directly challenges the inhibition hypothesis. The University of Milan’s 2025 Circulation Research findings on local arterial-wall activation represent a mechanistically distinct approach that may bypass the MR concern entirely. The first confirmed Phase I human data from Milan — once ClinicalTrials.gov registration is verified — will be the field’s most important near-term catalyst.
Dashboard Data Points
- Overview
- Development Timeline
- Efficacy Comparison
- FDA Regulatory
- PLTP Evidence
- Commercialization
- Risks & Gaps
